ArticleEuropean journal of radiology open2026
Role of apparent diffusion coefficient (ADC) and MRI-derived parameters in identifying p53-abnormal subtypes of endometrial cancer.
Article in European journal of radiology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-invasive imaging techniques such as magnetic resonance imaging (MRI) offer advantages over repeated biopsies for assessing tumor characteristics, though histological and molecular analysis remain the diagnostic gold standard. Since P53 expression is an important prognostic factor linked to the histopathological patterns of endometrial cancer (EC), using MRI-derived indices to distinguish between TP53-mutated (P53abn) and non-P53abn subtypes is clinically practical. This study aimed to determine the predictive value of MRI-based markers, especially apparent diffusion coefficients (ADC), for differentiating P53abn and non-P53abn subtypes in patients with EC. Methods: This retrospective study was performed on 115 patients with known EC. All MR imaging studies were performed on 1.5 T MR imaging units. The presence of p53abn subtype was determined by immunohistochemical staining (IHC). Data were analyzed using R version 4.4.1. Results: A statistically significant difference was observed in mean ADC values between patients with and without p53abn by IHC, with notably lower ADC values in the P53abn group. However, no significant association was identified between P53abn status and other imaging parameters, such as mass T2, outer myometrium T2, or the mass-to-psoas intensity ratio. Multivariable logistic regression analysis identified ADC value and tumor's histological subtype as the primary determinants of p53abn EC. ROC curve analysis further demonstrated that ADC measurement could effectively predict p53abn. The best cutoff point of ADC to discrimination was 695, yielding a sensitivity of 100% and specificity of 83%. Conclusion: In patients with EC, assessing tumor ADC values on MRI can serve as a valuable tool for predicting p53abn subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.